Latigo Launches into Non-Opioid Pain Medicine Space with $135 Million Series A

Vertex’s recent announcement that its VX-548, led to “significant improvement” in pain in Phase III clinical trials awakened interest in the long-stalled non-opioid pain medicine field, and on Wednesday, a new player, Latigo Biotherapeutics, debuted with $135 million in Series A financing.